ライフサイエンスコーパス: hydroxysteroid

1 NADPH-dependent reduction of ketosteroids to hydroxysteroids.

2 ransport, and sulfonylation of bile acids or hydroxysteroids.

3 abolism of androgenic and neuroactive 3alpha-hydroxysteroids.

4 ing pregnenolone and progesterone to 17alpha-hydroxysteroids.

5 atalyzes metabolism of retinoids and 3 alpha-hydroxysteroids.

6 characterized the functional effect of 3beta-hydroxysteroids.

7 ns of barbiturates was also reduced by 3beta-hydroxysteroids.

8 ation of synaptic currents induced by 3alpha-hydroxysteroids.

9 th a k(cat)/K(m) similar to that for 20alpha-hydroxysteroids.

10 ompetent kinetics) plus hydroxylated 17alpha-hydroxysteroids.

11 dipose tissue (WAT) genes but also represses hydroxysteroid 11-beta-dehydrogenase 1 (HSD11B1) indepen

12 On the other hand, LSD1 represses HSD11B1 (hydroxysteroid 11-beta-dehydrogenase isozyme 1), a key g

13 another deceased case (SF) with undetectable hydroxysteroid (17beta) dehydrogenase 10 (HSD10) activit

14 of the neurological handicap associated with hydroxysteroid (17beta) dehydrogenase 10 deficiency.

15 Approximately half of the cases of hydroxysteroid (17beta) dehydrogenase X (HSD10) deficien

16 s reduced the potentiation induced by 3alpha-hydroxysteroids, 3beta-hydroxysteroids acted noncompetit

17 ion induced by 3alpha-hydroxysteroids, 3beta-hydroxysteroids acted noncompetitively with respect to p

18 encompassing 3-hydroxyacyl-CoA derivatives, hydroxysteroids, alcohols and beta-hydroxybutyrate, and

19 codes a sulfoconjugation enzyme that acts on hydroxysteroids and cholesterol-derived sterol bile acid

20 effect on GABAergic synaptic currents, 3beta-hydroxysteroids and low concentrations of sulfated stero

21 3beta-Hydroxysteroids are also direct, noncompetitive GABA(A)

22 3beta-Hydroxysteroids coapplied with GABA significantly inhibi

23 ne, indicating Delta4-ketosteroids to Delta5-hydroxysteroids conversion, provides strong evidence for

24 dology for the quantitative determination of hydroxysteroids dehydroepiandrosterone and pregnenolone

25 hat mediates sulfo-conjugation of endogenous hydroxysteroids (dehydroepiandrosterone, testosterone, b

26 Two isozymes of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) interconvert

27 target receptors and the isozymes of 11beta-hydroxysteroid dehydrogenase (11 beta-HSD) that regulate

28 Isozymes of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) act at a prere

29 The 11beta-hydroxysteroid dehydrogenase (11beta-HSD) enzymes contro

30 ly of systemic levels, by isozymes of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) that interconv

31 verting cortisone to cortisol via the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 pathway

32 ,12(2)H3] cortisol (D3-cortisol) via 11-beta hydroxysteroid dehydrogenase (11beta-HSD) type 1, D3-cor

33 ra with a luminal signaling sequence (11beta-hydroxysteroid dehydrogenase (11beta-HSD1)(1-41)/Rdh1(23

34 ery of potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase (11beta-HSD1).

35 The kidney also expresses both of the 11beta-hydroxysteroid dehydrogenase (11betaHSD) enzymes.

36 11beta-Hydroxysteroid dehydrogenase (11betaHSD) isozymes cataly

37 s study, we have examined the role of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 2 in the

38 tive metabolizing enzyme, the type II 17beta-hydroxysteroid dehydrogenase (17beta-HSD), in the ZR-75-

39 ls in HEK293 cells expressing type 10 17beta-hydroxysteroid dehydrogenase (17beta-HSD10), but not its

40 steroid-5alpha-reductase (SRD5A) and 17beta-hydroxysteroid dehydrogenase (17betaHSD) isoenzymes.

41 ctivation of a steroidogenic enzyme, 20alpha-hydroxysteroid dehydrogenase (20alpha-HSD), which in tur

42 ssor of the P(4)-metabolizing enzyme 20alpha-hydroxysteroid dehydrogenase (20alpha-HSD).

43 he progesterone inactivating enzyme 20-alpha-hydroxysteroid dehydrogenase (20alpha-HSD; median, 2.5 a

44 Human PGFS is 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD) type II and h

45 Rat liver 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD), an aldo-keto

46 DH-4 from a related enzyme, RoDH-like 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD), which is 3-fo

47 lpha-reductase type I (5alpha-RI) and 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD).

48 alpha-reductase (5alpha-R) type I and 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD).

49 these enzymes were analyzed using rat 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD, AKR1C9) as the

50 he source of NADPH-dependent cytosolic 3beta-hydroxysteroid dehydrogenase (3beta-HSD) activity is unk

51 The 3beta-hydroxysteroid dehydrogenase (3beta-HSD) isoenzymes play

52 converts cholesterol to pregnenolone), 3beta-hydroxysteroid dehydrogenase (3beta-HSD, converts pregne

53 of differentiated function, including 3beta-hydroxysteroid dehydrogenase (3betaHSD) activity.

54 We identified the 3-beta-hydroxysteroid dehydrogenase (3betaHSD) family member HS

55 Six isoforms of the enzyme 3beta-hydroxysteroid dehydrogenase (3betaHSD) have been identi

56 mmonly requires enzymatic reactions by 3beta-hydroxysteroid dehydrogenase (3betaHSD), steroid-5alpha-

57 50, aldehyde dehydrogenase (ALDH3A2), and 21-hydroxysteroid dehydrogenase (AKR1C18) were found to be

58 Type I human hepatic 3alpha-hydroxysteroid dehydrogenase (AKR1C4) plays a significan

59 The enzyme 11beta-hydroxysteroid dehydrogenase (HSD) type 1 converts inact

60 Flux through the 11beta hydroxysteroid dehydrogenase (HSD) type 1 pathway can be

61 e crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase (HSD)/bile acid binding pro

62 rogenase 4 (RoDH4, SDR9C8), RoDH-like 3alpha-hydroxysteroid dehydrogenase (RL-HSD, SDR9C6), and RDH-l

63 We tested this by expressing 11-beta-hydroxysteroid dehydrogenase (type II) in dentate gyrus

64 Expression of 11-beta-hydroxysteroid dehydrogenase (type II), mostly in mature

65 11beta-Hydroxysteroid dehydrogenase 1 (11beta-HSD1) has been a

66 e metabolism through its induction of 11beta-hydroxysteroid dehydrogenase 1 (HSD1) and glucocorticoid

67 Regulation of 11 beta-hydroxysteroid dehydrogenase 1 expression is important s

68 The 17beta-hydroxysteroid dehydrogenase 1 gene (HSD17B1) encodes 17

69 8[TTTTA]n) or CYP17A1 (-34T/C) or the 17beta-hydroxysteroid dehydrogenase 1 gene HSD17B1 (Ser312Gly)

70 Lower relative abundance of 11-beta-hydroxysteroid dehydrogenase 1 mRNA in HG explants sugge

71 loid A3, stearoyl-CoA desaturase, and 11beta-hydroxysteroid dehydrogenase 1 were induced while actin

72 lucose elimination, and inhibitors of 11beta-hydroxysteroid dehydrogenase 1, which reduce the glucoco

73 hich was induced by both agents, and 11 beta-hydroxysteroid dehydrogenase 1, which was decreased by t

74 gous and are most closely related to 17-beta-hydroxysteroid dehydrogenase 1.

75 converted to active corticosterone by 11beta-hydroxysteroid dehydrogenase 1.

76 controls negative feedback mechanism, 11beta-hydroxysteroid dehydrogenase 2 (11betaHSD2).

77 17beta-Hydroxysteroid dehydrogenase 2 (17beta-HSD2) catalyzes t

78 e inner mitochondrial membrane protein 3beta-hydroxysteroid dehydrogenase 2 (3betaHSD2) synthesizes p

79 ated by the inner mitochondrial enzyme 3beta-hydroxysteroid dehydrogenase 2 (3betaHSD2).

80 the glucocorticoid receptor and the 11-beta hydroxysteroid dehydrogenase 2 isozyme were significantl

81 f the glucocorticoid receptor or the 11-beta hydroxysteroid dehydrogenase 2 isozyme.

82 dipose tissue compared to SC, whereas 17beta-hydroxysteroid dehydrogenase 5 (AKR1C3) showed predomina

83 ainly with mRNA and protein levels of 17beta-hydroxysteroid dehydrogenase 6 (17beta-HSD6), one of sev

84 tive loss of AKR1C1, which encodes a 20alpha-hydroxysteroid dehydrogenase [20alpha-HSD (EC 1.1.1.149)

85 .1.149)], and AKR1C2, which encodes a 3alpha-hydroxysteroid dehydrogenase [3alpha-HSD (EC 1.1.1.52)],

86 %), but does not have the retinol and 3alpha-hydroxysteroid dehydrogenase activity of either, nor is

87 ens with high positional selectivity (17beta-hydroxysteroid dehydrogenase activity) as well as 3-keto

88 oblasts express significant oxidative 3alpha-hydroxysteroid dehydrogenase activity, which can convert

89 by reduced progesterone secretion and 3beta-hydroxysteroid dehydrogenase activity.

90 with inhibitors of type 1- and type 2-17beta hydroxysteroid dehydrogenase did not affect the previous

91 s derived from DHT by 3-keto reductase/3beta-hydroxysteroid dehydrogenase enzymes.

92 Disruption of the 3beta-hydroxysteroid dehydrogenase gene in Mtb abrogates mycob

93 ted levels of P4-metabolizing enzyme 20alpha-hydroxysteroid dehydrogenase in corpora lutea (CL) inact

94 he Rv1106c gene that is annotated as a 3beta-hydroxysteroid dehydrogenase in Mtb has been cloned and

95 The expression of the 3beta-hydroxysteroid dehydrogenase in Mtb is intracellular.

96 te expression of 5alpha-reductase and 3alpha-hydroxysteroid dehydrogenase mRNAs in the NTS, and this

97 GR and NF1 binding on the endogenous 11beta-hydroxysteroid dehydrogenase promoter, also regulated by

98 dihydrotestosterone (DHT) and/or its 3alpha-hydroxysteroid dehydrogenase reduced metabolite 3alpha-a

99 tion enzyme was identified as a novel 17beta-hydroxysteroid dehydrogenase responsible for the inactiv

100 r glucocorticoid reamplifying enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD-1) foun

101 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) catal

102 tive 11-keto forms through the enzyme 11beta hydroxysteroid dehydrogenase type 1 (11beta HSD-1).

103 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) catal

104 In adipocytes, the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) conve

105 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) intra

106 ion of D4 cortisol to D3 cortisol via 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) occur

107 11Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) amplif

108 The cortisol-regenerating enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) amplif

109 11Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) cataly

110 In vivo, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) cataly

111 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) conver

112 heses of AMG 221 (2), an inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) discov

113 novel, potent inhibitor against human 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme

114 The 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme

115 urs through increased activity of the 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme

116 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) has be

117 the glucocorticoid-generating enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in adi

118 xpression of the GC-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in cul

119 tion of glucocorticoids by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in fat

120 neration of active glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in met

121 from a rapidly metabolized adamantane 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibi

122 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is the

123 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is the

124 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is the

125 ve glucocorticoid by NADPH-dependent, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) oxored

126 glucocorticoids in vivo by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) plays

127 ification of glucocorticoids (GCs) by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) plays

128 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) regene

129 The enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) regene

130 a defect in the gene HSD11B1 encoding 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), a pri

131 cocorticoid (GC) regenerating enzyme, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), in ad

132 nd that tissue regeneration of GCs by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), rathe

133 glucocorticoid metabolism, including 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), which

134 to be potent inhibitors of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).

135 sulin resistance and are regulated by 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).

136 racellular cortisone-cortisol shuttle 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).

137 regulated by the GC-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).

138 We investigated whether inhibition of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1, also k

139 ular glucocorticoid-amplifying enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1(-/-)) ha

140 CP2, glucocorticoid receptor (GR) and 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) and 2 (

141 culum by an enzyme complex containing 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) and hex

142 11beta-Hydroxysteroid dehydrogenase type 1 (11betaHSD1) catalyz

143 11beta-Hydroxysteroid dehydrogenase type 1 (11betaHSD1) is a th

144 P2), glucocorticoid receptor (GR) and 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) mRNA in

145 11beta-Hydroxysteroid dehydrogenase type 1 (11betaHSD1) perform

146 tion of glucocorticoids by the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1).

147 17beta-Hydroxysteroid dehydrogenase type 1 (17beta-HSD1) is tho

148 nt estrogen in human, is catalyzed by 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).

149 on that leads to a gain-of-function in 3beta-hydroxysteroid dehydrogenase type 1 (3betaHSD1), which c

150 I-MS/MS) was used to observe in vitro 11beta-hydroxysteroid dehydrogenase type 1 (HSD1) enzyme-cataly

151 family 11, subfamily A1 (CYP11A1) and 3 beta-hydroxysteroid dehydrogenase type 1 (HSD3B1) also down-r

152 oid secretion and metabolism (notably 11beta-hydroxysteroid dehydrogenase type 1 and 5alpha-reductase

153 er reviews the functional role(s) of 11 beta-hydroxysteroid dehydrogenase type 1 and examines factors

154 polymorphisms in the genes encoding 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phospha

155 trate that the reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 depends on reduced n

156 In mice, overexpression of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose or liver

157 Thus, 11 beta-hydroxysteroid dehydrogenase type 1 is a promising drug

158 In obese humans, 11 beta-hydroxysteroid dehydrogenase type 1 is relatively highly

159 Hexose-6-phosphate dehydrogenase and 11 beta-hydroxysteroid dehydrogenase type 1 may play important r

160 d activity because global deletion of 11beta-hydroxysteroid dehydrogenase type 1 normalized Ca(2+) an

161 , respectively, whereas mice lacking 11 beta-hydroxysteroid dehydrogenase type 1 resist diet-induced

162 ortisol by the reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1, which can thus incr

163 d for the 11-oxoreductase activity of 11beta-hydroxysteroid dehydrogenase type 1, which converts inac

164 17beta-Hydroxysteroid dehydrogenase type 10 (HSD10) is multifun

165 The enzyme 17beta-hydroxysteroid dehydrogenase type 10 (HSD10), also known

166 ion, and metabolic functions of human 17beta-hydroxysteroid dehydrogenase type 10/short chain L-3-hyd

167 cental glucocorticoid inactivation by 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) plays

168 The expression of 11beta hydroxysteroid dehydrogenase type 2 (11beta-HSD2) was ag

169 centa) or inhibitors of fetoplacental 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), the p

170 Expression of MR was similar, as was 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), which

171 th >10000-fold selectivity over human 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2).

172 11b2(-/-) mice, which lack the enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) and thu

173 The reduced activity of 11beta hydroxysteroid dehydrogenase type 2 (11betaHSD2) contrib

174 nction mutations in the gene encoding 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2), allowi

175 fects of GCs, in part by induction of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2).

176 In the adrenals, testes, and ovaries, 3beta-hydroxysteroid dehydrogenase type 2 (3betaHSD2) catalyze

177 c acute regulatory protein (StAR), and 3beta-hydroxysteroid dehydrogenase type 2 (3betaHSD2) via its

178 zyme with sequence homology to CD13), 11beta-hydroxysteroid dehydrogenase type 2 (a steroid pathway e

179 These neurons express the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2) and are activ

180 terone-sensitive neurons that express 11beta-hydroxysteroid dehydrogenase type 2 (HSD2) in the nucleu

181 e glucocorticoid-inactivating enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2), a signature

182 abel neurons in the NTS that express 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2), an enzyme th

183 locorticoid receptors and the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2), which makes

184 n of neurons that express the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2), which makes

185 TS neurons, which express the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2).

186 of the NTS, which express the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2).

187 n of neurons that express the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2).

188 ue to their expression of the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2).

189 ive neurons which contain the enzyme 11 beta-hydroxysteroid dehydrogenase type 2 (HSD2).

190 3beta-Hydroxysteroid dehydrogenase type 2 (HSD3B2) is a steroi

191 mangiomas were identified, including 17-beta hydroxysteroid dehydrogenase type 2 and tissue factor pa

192 Mutations in 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) cause

193 ptors, transgenic mice overexpressing 11beta-hydroxysteroid dehydrogenase type 2 in cardiomyocytes we

194 t the ability of the placental enzyme 11beta-hydroxysteroid dehydrogenase type 2 to inactivate cortis

195 izin (a potent inhibitor of placental 11beta-hydroxysteroid dehydrogenase type 2, the "barrier" to ma

196 ctus solitarius expresses the enzyme 11-beta-hydroxysteroid dehydrogenase type 2, which makes them se

197 The HSD2 (11-beta-hydroxysteroid dehydrogenase type 2-expressing) neurons

198 lasts via transgenic (tg) expression of 11ss-hydroxysteroid dehydrogenase type 2.

199 onal variants: HSD17B4, which encodes 17beta-hydroxysteroid dehydrogenase type 4 (HSD17B4), also know

200 s comparable with that of peroxisomal 17beta-hydroxysteroid dehydrogenase type 4.

201 response element-luciferase reporter, 17beta-hydroxysteroid dehydrogenase type 6 (17betaHSD6) convert

202 Human 11beta-hydroxysteroid dehydrogenase type I (11beta-HSD1) is an

203 lucocorticoid receptor (GR)-alpha and 11beta-hydroxysteroid dehydrogenase type I (11beta-HSD1)-mediat

204 cortisone to cortisol is catalyzed by 11beta-hydroxysteroid dehydrogenase type I (11beta-HSD1).

205 We found that expression of 11beta-hydroxysteroid dehydrogenase type II (11betaHSD2), which

206 Androgen biosynthesis requires 3beta-hydroxysteroid dehydrogenase type II (3betaHSDII) and th

207 to show that inhibition of the enzyme 11beta-hydroxysteroid dehydrogenase type II(11betaHSD2) reduces

208 to as the human bile acid binder and 3alpha-hydroxysteroid dehydrogenase type III, is a multifunctio

209 ffects of exogenous estradiol (E2) on 17beta-hydroxysteroid dehydrogenase type IV (HSD17B4) and the c

210 We focused on a Z-linked gene, 17beta-hydroxysteroid dehydrogenase type IV (HSD17B4), coding f

211 11beta-Hydroxysteroid dehydrogenase type-1 (11beta-HSD1) conver

212 11beta-hydroxysteroid dehydrogenase type-1 (HSD1) regulates con

213 roteins including cytochrome b(5) and 11beta-hydroxysteroid dehydrogenase were degraded slowly or not

214 l type of microsomal NAD(+)-dependent 3alpha-hydroxysteroid dehydrogenase with unique catalytic prope

215 aldo-keto reductase AKR1C1 (20alpha(3alpha)-hydroxysteroid dehydrogenase) is induced by electrophili

216 do-keto reductase 1C3 (AKR1C3; type 5 17beta-hydroxysteroid dehydrogenase) is overexpressed in castra

217 Rv1106c (hsd; 3beta-hydroxysteroid dehydrogenase) is required by Mycobacteri

218 esizing enzymes (5alpha-reductase and 3alpha-hydroxysteroid dehydrogenase) was increased in the hypot

219 oteins involved in steroid biogenesis (e.g., hydroxysteroid dehydrogenase), antioxidant functions (e.

220 Type 5 17beta-hydroxysteroid dehydrogenase, aldo-keto reductase 1C3 (A

221 teroidogenic acute regulatory protein, 3beta-hydroxysteroid dehydrogenase, and P450c17) was impaired.

222 a-reductase, 6alpha-hydroxylase, 3alpha/beta-hydroxysteroid dehydrogenase, and reverse Delta4minus si

223 The enzyme is most efficient as a 3alpha-hydroxysteroid dehydrogenase, converting 3alpha-tetrahyd

224 in expression of 5alpha-reductase and 3alpha-hydroxysteroid dehydrogenase, especially in cerebellum.

225 chain cleavage enzyme, P450 aromatase, 3beta-hydroxysteroid dehydrogenase, luteinization hormone rece

226 Human type 3 3alpha-hydroxysteroid dehydrogenase, or aldo-keto reductase (AK

227 In summary, in addition to 3alpha-hydroxysteroid dehydrogenase, rat osteoblasts express si

228 ocorticoid binding by the absence of 11-beta hydroxysteroid dehydrogenase, salt-mineralocorticoid-ind

229 enveloped virus host range protein, dUTPase, hydroxysteroid dehydrogenase, superoxide dismutase, serp

230 than reported for 3alpha-reduction by 3alpha-hydroxysteroid dehydrogenase, the major enzyme known to

231 17-beta-Hydroxysteroid dehydrogenase, type 7, was identified onl

232 cocorticoid (GC) metabolising enzyme, 11beta-hydroxysteroid dehydrogenase-1 (11beta-HSD1) converts in

233 d compounds, acting by inhibition of 11-beta-hydroxysteroid dehydrogenase-1 (11beta-HSD1), gave rise

234 Deficiency of placental 11beta-hydroxysteroid dehydrogenase-2 (11beta-HSD2), which inac

235 in E3-ligase, AMFR, mediating loss of 11beta-hydroxysteroid dehydrogenase-2 (11beta-HSD2), which othe

236 Human ECs also express the enzyme 11-beta-hydroxysteroid dehydrogenase-2 (11betaHSD2), and inhibit

237 for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male E

238 We identified hydroxysteroid dehydrogenase-3beta isotype 4 and osteopo

239 The HSD2 (11-beta-hydroxysteroid dehydrogenase-type 2 enzyme) containing n

240 her, nor is it active as a 17beta- or 11beta-hydroxysteroid dehydrogenase.

241 receptor level by the two isozymes of 11beta-hydroxysteroid dehydrogenase.

242 rt chain dehydrogenase, DHS-16, as a novel 3-hydroxysteroid dehydrogenase.

243 HSD-1 is orthologous to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase

244 As skin expresses 3alpha/beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerases, c

245 or P450 side chain cleavage and Delta5-3beta-hydroxysteroid dehydrogenase/Delta5-Delta4- isomerase en

246 The enzyme 3 beta-hydroxysteroid dehydrogenase/isomerase (3 beta-HSD) is e

247 Human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase (3 beta-HSD/isome

248 tissues) and type 2 (adrenals, gonads) 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD/isomer

249 pe 2 (adrenals and gonads) isoforms of 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD1 and 3

250 es of unknown function (e.g., D127 in 3 beta-hydroxysteroid dehydrogenase/isomerase-1).

251 opment of a fluorogenic substrate for 17beta-hydroxysteroid-dehydrogenase type 10 (17beta-HSD10), whi

252 ess the cortisol-inactivating enzyme 11-beta-hydroxysteroid-dehydrogenase-2 (11betaHSD2).

253 cholestan-3beta,5alpha-diol (OCDO) by 11beta-hydroxysteroid-dehydrogenase-type-2 (11betaHSD2).

254 renal axis, and the activities of the 11beta-hydroxysteroid dehydrogenases (11-HSDs) that interconver

255 11beta-hydroxysteroid dehydrogenases (11beta-HSD) perform prere

256 11beta-hydroxysteroid dehydrogenases (11beta-HSDs) catalyse the

257 ptor metabolism of glucocorticoids by 11beta-hydroxysteroid dehydrogenases (11beta-HSDs) modulates ce

258 R), glucocorticoid receptor (GR), and 11beta-hydroxysteroid dehydrogenases (11beta-HSDs).

259 The 17beta-hydroxysteroid dehydrogenases (17beta-HSDs) catalyze the

260 3Alpha-hydroxysteroid dehydrogenases (3alpha-HSDs) catalyze the

261 anolone biosynthesis, is catalyzed by 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs).

262 3beta-hydroxysteroid dehydrogenases (HSD3Bs), encoded by the H

263 Hydroxysteroid dehydrogenases (HSDs) are essential for t

264 s high selectivity in living cells for human hydroxysteroid dehydrogenases (HSDs) of the aldo-keto re

265 forms have been shown to act as 3alpha/3beta-hydroxysteroid dehydrogenases (HSDs) on 5alpha-dihydrote

266 4)-3-ketosteroids, whereas AKR1C enzymes are hydroxysteroid dehydrogenases (HSDs).

267 GR), mineralocorticoid receptor (MR), 11beta-hydroxysteroid dehydrogenases 1 and 2 (11beta-HSD1 and 1

268 zymes are closely related to the short-chain hydroxysteroid dehydrogenases and differ substantially f

269 Several hydroxysteroid dehydrogenases of the AKR1C subfamily cat

270 and encodes a protein with homology to 3beta-hydroxysteroid dehydrogenases that functions in one of t

271 ature distinguishes it from all known 17beta-hydroxysteroid dehydrogenases, and endows mitochondria w

272 and access to nuclear receptors by acting as hydroxysteroid dehydrogenases.

273 a conversion catalyzed by one or more 17beta-hydroxysteroid dehydrogenases.

274 ntermediates suggested a deficiency of 3beta-hydroxysteroid-delta8,delta7-isomerase (sterol-delta8-is

275 ensitive to both the direct effects of 3beta-hydroxysteroids on GABA(A) responses and the reduction o

276 oid reductase activity of the enzymes, their hydroxysteroid oxidase activity was potently inhibited b

277 Cs also expressed substantial 3alpha[17beta]-hydroxysteroid oxidase activity with 3alpha-Diol as the

278 progesterone (P4)'s 5 alpha-reduced, 3 alpha-hydroxysteroid oxidoreduced product, facilitates lordosi

279 uctase inhibitor, or indomethacin, a 3 alpha-hydroxysteroid oxidoreductase inhibitor, either systemic

280 wer than in group-housed mice whereas 3alpha-hydroxysteroid oxidoreductase mRNA expression was equal

281 lic reduction by 5alpha-reductase and 3alpha-hydroxysteroid oxidoreductase to form 5alpha-dihydrodeox

282 methacin (100 mg/kg), an inhibitor of 3alpha-hydroxysteroid oxidoreductase.

283 Although 3beta-hydroxysteroids reduced the potentiation induced by 3alp

284 near (typical R2 is superior to 0.98 for all hydroxysteroids studied) over the concentration range of

285 ol (E2) but insignificant ability to sulfate hydroxysteroids such as dehydroepiandrosterone (DHEA).

286 oepiandrosterone sulfotransferase (STD) is a hydroxysteroid sulfo-conjugating enzyme with preferentia

287 Glucocorticoid-inducible hydroxysteroid sulfotransferase (SULT2-40/41) gene trans

288 te from a previously determined structure of hydroxysteroid sulfotransferase (SULT2A1) binding dehydr

289 The gene for human hydroxysteroid sulfotransferase (SULT2B1) encodes two pe

290 of an alternative exon 1, the gene for human hydroxysteroid sulfotransferase (SULTB1) encodes for two

291 ite-selected mutagenesis of this 3alpha/beta-hydroxysteroid sulfotransferase chimera involving the 12

292 -glucuronosyltransferase 1A1, 1A3, 1A4, 1A6, hydroxysteroid sulfotransferase enzyme 2A1, multidrug re

293 SNPs in the hydroxysteroid sulfotransferase, SULT2A1, have been iden

294 e 5'-phosphosulfate, and either rat or human hydroxysteroid sulfotransferase, the formation of DNA ad

295 The 3-hydroxysteroid sulfotransferases that have been isolated

296 ifene was a poor substrate for rat and human hydroxysteroid sulfotransferases.

297 This direct, noncompetitive effect of 3beta-hydroxysteroids was sufficient to account for the appare

298 Hydroxysteroids were extracted using methanol and steroi

299 d external neurosteroid antagonist site, and hydroxysteroids, which bind an independent site, are eff

300 e exhibits an oxidoreductase activity toward hydroxysteroids with NAD(+) and NADH as the preferred co